Form 4: Avalo Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., sold 10,185 shares of common stock on September 10, 2026 for $17.62 per share.
Summary
- Option exercise/conversion: acquired 10,185 Common Stock at $8.04 ($81,887) on September 10, 2026; holds 50,085 after (Direct).
- Open-market sale: disposed of 10,185 Common Stock at $17.62 ($179,457) on September 10, 2026; holds 39,900 after (Direct).
- Option exercise/conversion: disposed of 10,185 Stock Option (Right to Buy) on September 10, 2026; holds 105,815 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $179,457 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Ryan Sullivan — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 10,185 | $8 | $81.9K | 50,085 |
| 2026-09-10 | Open-market sale | Common Stock | 10,185 | $18 | $179.5K | 39,900 |
| 2026-09-10 | Option exercise/conversion | Stock Option (Right to Buy) | 10,185 | — | — | 105,815 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (10,185 shares) |
| 2026-09-10 | Open-market sale (10,185 shares) |
| 2026-09-10 | Option exercise/conversion (10,185 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., bearish, Christopher Ryan Sullivan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.